Nasdaq rvnc

Revance Therapeutics, Inc. About the company. The company's lead drug candidate is DAXXIFY DaxibotulinumtoxinA-lanm for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar nasdaq rvnc.

See all ideas. See all brokers. EN Get started. Market closed Market closed. No trades. RVNC chart. Key stats.

Nasdaq rvnc

.

Does Revance Therapeutics, Inc. Like other stocks, RVNC shares are traded on stock exchanges, e.

.

Key events shows relevant news articles on days with large price movements. Karyopharm Therapeutics Inc. KPTI Evolus Inc. EOLS 1. Li Auto Inc.

Nasdaq rvnc

We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service. ZacksTrade and Zacks. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. OK Cancel. Add to portfolio.

Canada mustang parts

Waugh and L. Forecast to breakeven in Jan Senior VP notifies of intention to sell stock Sep View Valuation. EN Get started. Market capitalization. Revenue to profit conversion. Keep track of upcoming events with our Earnings Calendar. New minor risk - Profitability Nov Net income. Keep reading Keep reading. No trades.

.

RVNC reached its all-time high on Nov 11, with the price of Beta 1Y. The firm focuses on production of daxibotulinumtoxinA, a botulinum toxin, for aesthetic and therapeutic indications including facial wrinkles and muscle movement disorders. See other stocks reaching their highest and lowest prices. Analyst rating. Learn more. Like other stocks, RVNC shares are traded on stock exchanges, e. The company's lead drug candidate is DAXXIFY DaxibotulinumtoxinA-lanm for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. One year price forecast for Revance Therapeutics, Inc. How do Revance Therapeutics's earnings and revenue compare to its market cap? Hollander as Chief Medical Officer Oct One year price forecast for Revance Therapeutics, Inc. Yes, you can track Revance Therapeutics, Inc. Net income.